Literature DB >> 14681093

Predictors of outcome for myasthenia gravis after thymectomy.

Yasser El-Medany1, Waseem Hajjar, Mohamed Essa, Khaled Al-Kattan, Zohair Hariri, Mahmoud Ashour.   

Abstract

The aim of this study was to assess the clinical outcome of patients with myasthenia gravis treated with maximal thymectomy and to identify prognostic variables that predict the outcome. Over 15 years, from 1986 to 2001, we collected data on 100 patients with myasthenia gravis who underwent maximal thymectomy and retrospectively reviewed their outcome. Women comprised 63% and the median age was 25 years (range, 4 to 61). The median duration of the disease was 26 months (range, 1 to 240). According to the Osserman classification, there were seven patients in class I, 31 in class II, 47 in class III, and 15 in class IV. In non thymomatous patients (93 patients), complete remission rate progressively increased from 37.4% to 58.2% and 75% at 3, 10 and 15 years of follow-up respectively. These findings suggest that the complete remission rate is prone to increase with time after maximal thymectomy. The total benefit rate achieved was estimated to be 86% while 14% did not improve at a mean follow-up period of 7.6 years (range, 8 to 180 months). Univariate analysis (p < 0.05) showed that age, thymic histology and ectopic thymic tissue are significant prognostic factors for outcome.

Entities:  

Mesh:

Year:  2003        PMID: 14681093     DOI: 10.1177/021849230301100411

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  7 in total

Review 1.  Is thymectomy in non-thymomatous myasthenia gravis of any benefit?

Authors:  Andres Diaz; Edward Black; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18

2.  Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis.

Authors:  Seung Woo Kim; Young-Chul Choi; Seung Min Kim; Hyo Sup Shim; Ha Young Shin
Journal:  J Neurol       Date:  2019-02-06       Impact factor: 4.849

3.  Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis.

Authors:  Z R Gao; C Kornblum; S Flacke; T Logvinski; M Yüksel; R An; T Klockgether; H J Biersack; S Ezziddin
Journal:  Neurol Sci       Date:  2007-08-10       Impact factor: 3.307

Review 4.  Unraveling the role of ectopic thymic tissue in patients undergoing thymectomy for myasthenia gravis.

Authors:  Feng Li; Ya Tao; Gero Bauer; Aron Elsner; Zhongmin Li; Marc Swierzy; Julianna Englisch; Andreas Meisel; Mahmoud Ismail; Jens-C Rückert
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

5.  Evaluation of extended thymectomy approaches based on residual fat tissue.

Authors:  Mitsuteru Yoshida; Masao Yuasa; Kazuya Kondo; Mitsuhiro Tsuboi; Naoya Kawakita; Akira Tangoku
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-22

6.  Preoperative plasmapheresis for elective thymectomy in myasthenia patient: is it necessary?

Authors:  Somcharoen Saeteng; Apichat Tantraworasin; Sophon Siwachat; Nirush Lertprasertsuke; Juntima Euathrongchit; Yuttaphan Wannasopha
Journal:  ISRN Neurol       Date:  2013-06-11

7.  Clinical Presentation, Management, and Outcome in Patients With Myasthenia Gravis: A Retrospective Study From Two Tertiary Care Centers in Saudi Arabia.

Authors:  Hussein Algahtani; Bader Shirah; Ali Alshehri; Abdulaziz N Al Hassani; Hosam H Binseddeq; Rayan M Mukhtar; Bashar Saleh; Jamal A Taj
Journal:  Cureus       Date:  2021-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.